Sajjala Bio to launch generic Liraglutide for diabetes, obesity by Dec 2019

Liraglutide has become a bio-generic in the markets where Novo Nordisk's patent has expired

Hyderabad-based Sajjala Bio Labs Private Limited announced on Friday that it was planning to commence clinical studies on recombinant Liraglutide for approval to manufacture and market the drug in countries where it went off-patent.

Sajjala Bio said it was the first company in India to have successfully completed the preclinical toxicology studies for recombinant Liraglutide, which is used for the treatment of type-2 diabetes and obesity.  

Copenhagen-headquartered global innovator drug company Novo Nordisk had held the patent for this product till September 2017 in India and other countries, according to Sajjala Bio. The innovator company sells this injectable drug under the